10-Q: Masimo Q3: Core Business Grows, Discontinued Ops Drag Net Loss

Masimo Corporation reported strong growth in its continuing healthcare operations for Q3 2025, but a significant net loss driven by the sale of its non-healthcare consumer business.

Summary

• Revenue from continuing operations increased by 8.2% to $371.5 million for the three months ended September 27, 2025, and by 8.5% to $1,114.4 million for the nine months ended September 27, 2025.
• Gross profit from continuing operations rose to 62.1% for the three months and 62.6% for the nine months ended September 27, 2025, up from 61.8% and 61.0% in the prior year periods, respectively.
• Operating income from continuing operations significantly increased by 118.8% to $83.6 million for the three months and by 69.6% to $226.1 million for the nine months ended September 27, 2025.
• Net income from continuing operations grew by 121% to $53.7 million for the three months and by 79.6% to $145.8 million for the nine months ended September 27, 2025.
• The company reported a net loss of $100.4 million for the three months and $219.8 million for the nine months ended September 27, 2025, primarily due to a $154.1 million and $365.6 million loss from discontinued operations, respectively.
• The non-healthcare consumer business (Sound United) was sold on September 23, 2025, for approximately $328 million net cash, resulting in significant impairment charges of approximately $295.0 million and closing adjustments.
• Cash and cash equivalents increased to $312.3 million as of September 27, 2025, from $123.6 million at December 28, 2024.
• Long-term debt was reduced to $559.1 million as of September 27, 2025, from $714.3 million at December 28, 2024, following a $271.1 million repayment on the Term Loan.

Sentiment

Score: 5

Explanation: While the core healthcare business shows strong operational performance and growth, the significant one-time loss from discontinued operations and the extensive, ongoing legal and regulatory challenges create substantial uncertainty and financial overhang. The positive core business trends are balanced by these considerable negative factors.

Positives

• Strong revenue growth in continuing healthcare operations, increasing 8.2% for the quarter and 8.5% for the nine months.
• Improved gross profit margins in continuing operations, reaching 62.1% for the quarter and 62.6% for the nine months, driven by operational efficiencies and product cost reductions.
• Significant increase in operating income from continuing operations, up 118.8% for the quarter and 69.6% for the nine months.
• Net income from continuing operations more than doubled for the quarter and increased by nearly 80% for the nine months.
• Successful divestiture of the non-healthcare consumer business (Sound United) for approximately $328 million net cash, allowing for refocus on the core healthcare segment.
• Substantial reduction in long-term debt by $155.2 million, improving the company's financial leverage.
• Cash and cash equivalents significantly increased to $312.3 million, enhancing liquidity.

Negatives

• Overall net loss of $100.4 million for the quarter and $219.8 million for the nine months, primarily due to losses from discontinued operations.
• Discontinued operations incurred significant intangible asset write-downs of approximately $295.0 million and closing adjustments.
• Ongoing and extensive litigation, including patent infringement, trade secret misappropriation, and antitrust claims against Apple, as well as internal disputes with former CEO Joe Kiani and Willow Laboratories.
• Regulatory scrutiny from the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) regarding a Rad-G product recall and alleged accounting irregularities.
• Cybersecurity incident in April 2025 temporarily impacted manufacturing and order processing, incurring $5.5 million in expenses (partially offset by insurance).
• Exposure to trade policies and tariffs, particularly on materials from China, Mexico, and Malaysia, which could negatively impact costs and profitability.
• Potential adverse effects from changes in U.S. government policies, including FDA workforce reductions and Medicaid spending cuts, which could impact product approvals and customer reimbursements.

Risks

• Changes in U.S. trade policies and tariffs could increase costs for raw materials and subassemblies, or require price increases, potentially decreasing customer demand and adversely impacting revenue and profitability.
• Reductions in FDA workforce and other personnel changes may disrupt regulatory reviews and approvals, impacting the timely release of new products and commercial viability.
• Estimated $1 trillion in Medicaid spending cuts from the One Big Beautiful Bill Act could reduce hospital revenues, adversely impacting sensor utilization and order patterns.
• Loss of any large customer or distributor, or cancellation/delay of significant purchases, could materially reduce net sales and harm operating results, especially given the concentration of sales through a few channels.
• Uncertainty and geopolitical instability from ongoing conflicts (Russia-Ukraine, Israel-Palestine-Iran) could impact business operations, particularly if conflicts escalate or expand.
• Extensive and costly legal proceedings, including patent infringement, trade secret misappropriation, and antitrust claims, could result in material fines, penalties, or other liabilities.
• Regulatory investigations by the DOJ and SEC related to product recalls and alleged accounting irregularities could lead to significant financial and managerial resource expenditure and potential liabilities.
• The company's ability to successfully execute its business plans and tax planning strategies, which are critical for realizing deferred tax assets, may be affected by future market conditions and other factors.

Future Outlook

The company remains optimistic about its long-term growth and prospects in the healthcare business, despite current market volatility. It is actively working to mitigate the impact of tariffs through supply chain adjustments, manufacturing changes, and seeking exemptions, while also evaluating alternative suppliers. The company anticipates that existing cash, available Credit Facility, and future cash from operations will adequately fund ongoing operating and capital expenditures, working capital, and other operational needs for the next 12 months. Additional funds may be sought through debt financing or other sources if required for future strategic investments.

Management Comments

• We continue to be optimistic about our long-term growth and prospects in our healthcare business.
• We are actively working to mitigate the operating profit impact of these tariffs with adjustments to our supply chain and manufacturing, as well as a significant amount of administrative effort to qualify our products for exemptions.
• We are also pursuing longer-term mitigation measures to further reduce our tariff exposure and evaluating alternative suppliers for raw materials and cables currently sourced from China.
• We anticipate that our existing cash and cash equivalents, amounts available under our Credit Facility and cash provided by operations and, taken together, provide adequate resources to fund on-going operating and capital expenditures, working capital requirements, and other operational funding needs for the next 12 months.

Industry Context

The healthcare market is highly competitive and dynamic, facing headwinds such as supply chain volatility, inflationary pressures, interest rate fluctuations, and geopolitical conflicts. Despite these challenges, Masimo's core healthcare business demonstrated strong growth and improved profitability, suggesting resilience and effective operational management. The divestiture of the non-healthcare consumer business allows the company to sharpen its focus on its core medical technology segment, aligning with a strategic realignment initiative to prioritize profitability and return on invested capital. However, the industry also faces regulatory changes, such as FDA workforce reductions and potential Medicaid spending cuts, which could impact market access and customer purchasing power.

Comparison to Industry Standards

• The company's gross profit margin of 62.1% (Q3 2025) and 62.6% (9M 2025) in its healthcare segment is competitive within the medical technology industry, often exceeding the average for diversified healthcare equipment and supplies companies, which typically range from 50-65%.
• The 8.2% revenue growth in the healthcare segment for Q3 2025 is robust, potentially outperforming some larger, more mature medical device companies that might see mid-single-digit growth, but could be in line with innovative, specialized segments.
• The significant increase in operating income (118.8% for Q3 2025) suggests strong cost control and operational leverage within the continuing operations, which is a positive indicator compared to industry peers facing similar inflationary pressures.
• The company's extensive and ongoing litigation with Apple, a major consumer electronics company, is a unique and substantial challenge not typically faced by most medical technology firms, making direct comparison difficult. However, the ITC ruling in Masimo's favor and subsequent enforcement actions demonstrate a strong intellectual property position against a formidable competitor.
• The divestiture of the non-healthcare consumer business, while resulting in a significant one-time loss, positions Masimo to focus on its core medical technology, a strategy often adopted by companies seeking to streamline operations and enhance shareholder value, similar to how larger conglomerates might spin off non-core assets.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing patent infringement, trade secret misappropriation, and inventorship claims against Apple Inc. in U.S. District Court, with a jury trial on patent infringement scheduled for November 4, 2025.
• U.S. International Trade Commission (ITC) found Apple violated Section 337, resulting in a Limited Exclusion Order (LEO) and Cease and Desist Order (CDO) against infringing Apple Watches; Apple's appeal is pending.
• Actions initiated against U.S. Customs and Border Protection and government officials regarding the importation of redesigned Apple Watches, including a motion for temporary restraining order and preliminary injunction.
• Apple's lawsuit against Masimo alleging infringement by the Masimo W1 watch, where a jury found no infringement by current products but infringement by discontinued versions, awarding Apple $250; Masimo's counterclaims for monopolization, false advertising, and antitrust are pending.
• Securities Class Action alleging materially false and misleading statements, where a settlement in principle has been reached and a motion for preliminary approval is pending.
• Derivative Actions alleging breach of fiduciary duties by current and former executives and directors, with an Amended Complaint filed and defendants' response due November 17, 2025.
• DOJ subpoena and civil investigative demand related to Rad-G and Rad-97 products, including a recall and customer returns, with the company investigating the delay in recall initiation.
• SEC subpoena seeking documents and information relating to allegations of potential accounting irregularities and internal control deficiencies from former employees.
• Litigation against former CEO Joe Kiani in Delaware Court of Chancery, seeking declarations that his employment agreement provisions (including a $35 million cash payment and 2.7 million RSUs) are invalid and unenforceable.
• Joe Kiani's lawsuits in California Superior Court, alleging wrongful termination for 'Good Reason' and seeking severance benefits, and a second lawsuit against individual Board Members for alleged Labor Code violations.
• RTW Litigation against Roderick Wong, Naveen Yalamanchi, RTW Investments, LP, and Joe Kiani for short-swing profits under Section 16(b) of the Exchange Act, with discovery ongoing.
• Arbitration demand filed by Willow Laboratories against the company, alleging breach of the Cross-Licensing Agreement and seeking at least $2.75 million in damages and specific performance.

Related Party Transactions

• Royalty expenses to Willow Laboratories under the Cross-Licensing Agreement were $5.5 million for the three months and $16.1 million for the nine months ended September 27, 2025, following an increase in minimum annual royalties to $15.0 million plus $2.0 million for an additional parameter after Mr. Kiani's termination.
• Willow Laboratories invoiced $12.8 million for remaining minimum royalty in Q1 2025, which was paid in Q2 2025.
• Administrative Services Agreement with Willow Laboratories was terminated effective April 30, 2025; no amounts charged by Masimo for Q3 2025.
• Lease agreement with Willow Laboratories expired December 31, 2024, and was not renewed, resulting in no lease income for Q3/9M 2025.
• Net amounts accrued and unpaid to Willow were approximately $4.1 million as of September 27, 2025.
• No cash contributions made to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare during Q3/9M 2025, with the company halting all payments as of Q3 2024 and not intending future contributions.
• Marketing service agreement with Like Minded Media Ventures (LMMV) was terminated in Q4 2024; no marketing expenses incurred in Q3/9M 2024.
• Aircraft time share agreement with Mr. Kiani was terminated upon his employment termination.
• Less than $0.1 million paid to Politan Capital Management LP in Q3/9M 2025; $2.0 million payment received from Politan related to legal expenses for 9M 2025.
• Sales to Cardinal Health, Inc. (where Michelle Brennan is a board member) were approximately $28.4 million for Q3 2025 and $86.0 million for 9M 2025.
• Amounts owed from Cardinal Health, Inc. were approximately $7.6 million as of September 27, 2025.

Stakeholder Impact

• Shareholders: Experience a significant net loss due to discontinued operations, but the core healthcare business shows strong performance. Ongoing litigation and regulatory investigations create uncertainty and potential for future liabilities, impacting share price volatility. The stock repurchase program aims to return value to shareholders.
• Employees: Management changes, including new executive hires, indicate a shift in leadership and strategic direction. The severance protection plan for executives provides security. The cybersecurity incident temporarily impacted operations, potentially affecting employee workflow.
• Customers: The cybersecurity incident caused temporary disruptions in order processing and fulfillment. The Rad-G product recall and associated investigations could impact customer trust and product availability. The sale of Sound United means the company will focus solely on healthcare customers.
• Suppliers: Changes in supply chain strategy to mitigate tariff impacts, including evaluating alternative suppliers, could affect existing supplier relationships.
• Creditors: Repayment of the Term Loan and reduction in long-term debt improve the company's credit profile. However, extensive litigation and potential liabilities could pose risks.

Next Steps

• Continue to pursue all claims against Apple vigorously and defend against Apple's claims.
• Proceed with discovery in the RTW Litigation regarding short-swing profits.
• Respond to the Amended Complaint in the Derivative Actions by November 17, 2025.
• Await the Court's decision on the motion for preliminary approval of class action settlement in the Securities Class Action.
• Continue cooperating with the DOJ and SEC in their investigations related to product recalls and accounting irregularities.
• Continue to investigate the reasons for the delay in the Rad-G product recall.
• Monitor and assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Actively work to mitigate the operating profit impact of tariffs through supply chain adjustments, manufacturing changes, and seeking exemptions.
• Evaluate alternative suppliers for raw materials and cables currently sourced from China.
• The jury trial on Apple's patent infringement claims is scheduled to begin on November 4, 2025.
• The company will reflect the adoption of ASU No. 2023-09 (Income Taxes) in its 2025 consolidated financial statements.
• The company is evaluating the impact of ASU No. 2024-03 (Expense Disaggregation Disclosures) and ASU No. 2025-05 (Credit Losses for Accounts Receivable) on its consolidated financial statements.
• The company is evaluating the impact of ASU No. 2025-06 (Internal-Use Software) on its consolidated financial statements.

Key Dates

Recommendation

While Masimo's core healthcare business demonstrates impressive growth in revenue, gross profit, and operating income, indicating strong underlying fundamentals and operational efficiency, the overall financial picture is significantly clouded by the substantial net loss from discontinued operations. The one-time impairment charges and closing adjustments related to the Sound United sale, though a strategic move to refocus, have a material negative impact on current earnings. Furthermore, the company faces extensive and costly litigation with Apple, internal disputes with its former CEO, and ongoing regulatory investigations from the DOJ and SEC. These legal and regulatory overhangs introduce considerable uncertainty and potential for future liabilities, which could weigh on the stock. The reduction in debt and increased cash position are positives for liquidity. A 'hold' recommendation is appropriate as the strong performance of the core business is offset by these significant, unresolved external and internal challenges, making it difficult to project clear upside until these issues are resolved or their financial impact becomes more predictable. Investors should monitor the progress of litigation and regulatory matters closely.

Keywords

Masimo, Healthcare Technology, Medical Devices, Patient Monitoring, SEC Filing, 10-Q, Financial Results, Divestiture, Sound United, Litigation, Apple, Joe Kiani, Regulatory Risk, Cybersecurity, Tariffs, Corporate Governance, Executive Changes